Key Points Lilly's pipeline is packed with metabolic health programs. Its commercialized metabolic health medicines are big earners. It's also buying assets and businesses at a fast pace. 10 stocks we like better than Eli Lilly › There's no rule that says a leading pharma stock can't go down. On that note, shares of Eli Lilly (NYSE: LLY) are still down by 7% from their recent high set in mid-August, even though its moneymaker metabolic medicines had powered 48% revenue growth in the second quarter. Some investors seem to be afraid that the company's willingness to sell those drugs at competitive prices will erode its margins.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.